These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37620320)

  • 1. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.
    Wu X; Xu L; Li X; Zhou Y; Han X; Zhang W; Wang W; Guo W; Liu W; Xu Q; Gu Y
    Cell Death Dis; 2023 Aug; 14(8):550. PubMed ID: 37620320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
    Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
    Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
    Hong X; Chen X; Wang H; Xu Q; Xiao K; Zhang Y; Chi Z; Liu Y; Liu G; Li H; Fang J; Lin T; Zhang Y
    Adv Sci (Weinh); 2023 Nov; 10(32):e2302377. PubMed ID: 37824205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression.
    Chen Z; Yuan J; Xu Y; Zhang C; Li Z; Gong J; Li Y; Shen L; Gao J
    Front Pharmacol; 2021; 12():757994. PubMed ID: 35069192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
    Qu F; Liu Q; Lu R; Li W
    Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
    Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
    Hu Y; Zhu Y; Wei X; Tang C; Zhang W
    Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
    Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
    Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
    Wang P; Xia L
    BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
    Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
    Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
    Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
    Lei H; Ling Y; Yuan P; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Han W; Hu C; Chi Z; Cui C; Si L; Fang J; Guo J; Sheng X; Zhou A; Ying J
    J Natl Cancer Cent; 2023 Jun; 3(2):121-128. PubMed ID: 39035731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
    Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
    Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
    Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
    Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.